Fully human anti-pneumococcal monoclonal antibodies
f (x) Immune Diagnostics, Inc. is honored to announce that we are now exclusively licensed for the fully human anti-pneumococcal antibody technology developed by Emory University and the Oklahoma Medical Research Institute.
Fully human mAbs raised against pneumococcal vaccine capsular polysaccharides are now available globally from our lab.
Available serotype-specific antibodies: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F, and cell wall polysaccharide.
For use in: assay development, quality programs, and free polysaccharide assays.
Product presentation: 200uL at 250ug/mL. Custom concentrations and volumes are available. Please contact us for more information.
“We have been researching solutions to reduce global mortality from pneumonia for over 20 years. Supplying these monoclonal antibodies to the industry will unlock many drug development and diagnostic possibilities to combat this illness,” said Joseph Martinez, Chief Science Officer at f (x) Immune.